

CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 8-K

August 29, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 28, 2013

CATALYST PHARMACEUTICAL

PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
(State or other jurisdiction

of incorporation)

001-33057
(Commission

File Number)

76-0837053
(I.R.S. Employer

Identification No.)

355 Alhambra Circle

Suite 1500

Coral Gables, Florida
(Address of principal executive offices)

33134
(Zip Code)

Registrant's telephone number, including area code: (305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 28, 2013, Catalyst Pharmaceutical Partners, Inc. ("Company") and its Chairman, President and Chief Executive Officer, Patrick J. McEnany, entered into an amendment to Mr. McEnany's employment agreement with the Company extending the term of such agreement for an additional three year period. Mr. McEnany's employment agreement with the Company now expires on November 8, 2016. All of the other terms of Mr. McEnany's employment agreement with the Company remain the same.

A copy of Amendment No. 4 to Mr. McEnany's employment agreement with the Company is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of Amendment No. 4 that is set forth above is qualified in its entirety by reference to such amendment.

Item 8.01 Other Events

On August 28, 2013, the Company received approximately \$1,378,000 upon the exercise of common stock purchase warrants to purchase an aggregate of 1,297,500 shares of the Company's common stock. A portion of the warrants that were exercised were originally issued in the Company's October 2011 registered direct offering, and the balance of the warrants that were exercised were issued in the Company's May 2012 public offering. The shares of common stock issued upon the exercise of these warrants are fully registered under the Securities Act of 1933.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

- 10.1 Amendment No. 4 to Employment Agreement between the Company and Patrick J. McEnany, dated August 28, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande
Alicia Grande
Vice President, Treasurer and CFO

Dated: August 28, 2013